Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amatuximab + Gemcitabine in Advanced Pancreatic Cancer
NCT00570713Phase 2Completed
- Sponsor
- Morphotek
- Start
- Dec 2007
- Primary completion
- Dec 2009
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing MORAb-009 + Gemcitabine with Placebo + Gemcitabine (2 arms). Primary endpoint: Overall Survival. Started Dec 2007; status: completed.
02
Drugs
amatuximab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00570713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00570713.